Omada Health (NASDAQ:OMDA) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
Omada Health (NASDAQ:OMDA) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
2026: When Women's Sport Becomes Healthcare's Most Powerful Platform [Forbes]
Omada Health Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2025
Omada Health (NASDAQ:OMDA) was upgraded by analysts at Wells Fargo & Company to a "hold" rating.